CAR-T cell therapy is among the most promising treatments being developed for hematological cancers. Although the engineered T cells used in the approach uniquely target a patient’s cancer cells, their quality varies widely between batches and patients. Minimizing hands on involvement in CAR-T cell development reduces some sources of this variation, and automation technology that processes cell products and evaluates their functions helps achieve this. Automation also reduces the risk for cell contamination, potentially facilitating both cell development and translation to clinical approval.
Download this technical note from IsoPlexis to learn more about
The Scientist c/o LabX Media Group
1000 N West Street, Suite 1200, Wilmington, Delaware, United States, 19801
Toll Free: 888.788.0328 | Phone: 705.528.6888
Email: privacy@the-scientist.com
© 1986-2022 The Scientist
The Scientist needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.